



ABN 82 010 975 612

Level 18, 101 Collins Street  
Victoria 3000 Australia  
Telephone: + 61 7 3273 9133  
Facsimile: + 61 7 3375 1168  
[www.tbgbio.com](http://www.tbgbio.com)

4 December 2017

## **ASX Announcement**

### **JV with China SOE to meet clinical diagnostic needs in Xiamen and Fujian**

#### **Highlights**

- **TBG to form 60/40 Joint Venture with Xiamen Hiancang Biotechnology Development Co.**
- **JV to build and operate a medical laboratory in TBG's Xiamen Biobay facility.**
- **Total commitment of AUD 6m to be spent on the JV.**

**Melbourne – December 4th, 2017** – TBG Diagnostics Limited (ASX: TDL) is pleased to announce that its wholly owned subsidiary, TBG Biotechnology Corp. will form a 60/40 joint venture with Xiamen Haicang Biotechnology Development Co (*Xiamen Haicang*).

Xiamen Haicang is a subsidiary of the Haitou Group, a 2 billion RMB conglomerate under Haicang government, Xiamen City in China.

The purpose of the Joint Venture is to build and operate a medical laboratory at TBG's facility located within the Xiamen Biobay, a 10-square-kilometer biomedicine industrial park home to more than 100 biomedical enterprises in Xiamen's Haicang district.

Both companies have committed to a total capital of 30 million RMB (AUD 6m) for the joint venture with TBG contributing 60% and Xiamen Haicang 40%. The first stage investment of 5m RMB (AUD 1m) will be used for the construction of the laboratory which will occupy 1,200 square meters and be located on the 3<sup>rd</sup> floor of TBG's premises in the BioBay.

The laboratory will serve the clinical diagnostic needs of hospitals in the Xiamen City as well as Fujian and neighbouring provinces in transplantation, blood and platelets transfusion, cancer and genetic diagnostics. In addition, as a technology platform, it will serve to support the companies in the Biobay for their needs in product research and developments.

The Xiamen government has recently given permission for the Joint Venture to establish the laboratory with the formal license expected in May 2018 when the construction of the laboratory is complete and staffing in place.

"Following receipt of our first CFDA approval in China for high resolution HLA typing products in October, this announcement means that TBG has taken a step further from product development and manufacturing to providing services to the health sector and especially by building partnership with an esteemed company like Xiamen Haicang." said Eugene Cheng, Group COO of TBG Diagnostics Limited.

#### **About TBG Diagnostics**

TBG Diagnostics is a global molecular diagnostic (MDx) company operating in the IVD (in vitro diagnostics) industry. TBG is focused on the development, manufacture and marketing of molecular diagnostic kits, instruments and services

TBG Diagnostics is an established brand with a strong presence in the Asian market. From its plant in Xiamen, China it develops and manufactures:

- Nucleic Acid Test (NAT) products
- HLA typing reagents based on NAT technologies
- Automation systems for NAT operations
- IVD-related NAT kits and services

Products distributed to more than 22 countries. Major hospital and laboratory clients in USA, Taiwan, Germany, Portugal, China, Hong Kong and Singapore. Operating in the rapidly growing IVD market - US\$53 billion in 2013 and expected to reach US\$74.7 billion by 2020.

Targeting further growth in China - fastest growing MDx market at CAGR of 27.9%. Extensive research and development pipeline targeting products for oncology, infectious diseases, transplants, transfusions, pharmacogenetics, autoimmune diseases and genetic diseases.